This randomized clinical trial was conducted to assess the effectiveness of cold compress on the severity of subcutaneous injection pain in the cardiac patients admitted to Ayatollah Rouhani hospital in Babol, Iran in 2015. The patients were divided into five groups, including a control group and four intervention groups.
The sampling process was performed at the cardiac section of the hospital; initially, the researchers selected the patients who were prescribed enoxaparin 6,000 units daily. Following that, the study groups were assigned a code each, and the codes were placed in a container. At the next stage, five envelopes labeled A, B, C, D, E (intervention groups), and F (control group) were selected and provided to the patients, who were blinded to the procedures. By drawing lots from the patient code container, a piece of paper was taken out, the desired code was selected from one of the envelopes, and the intervention groups were identified accordingly. At the next stage, the specified codes were returned to the container, so that the participants would have an equal chance to choose their intervention group. The process continued until reaching the desired sample size. Following that, each group received their specific treatment. The samples were selected from the patients admitted to the cardiology and CCU wards via convenience sampling. Notably, the wards were in the same medical center and covered by a joint healthcare team. As such, the type of the provided care and environmental conditions of the wards were also the same.
Sample size was determined to be 100 individuals in five groups of 20 based on the previous studies in this regard (
7). The inclusion criteria of the study were as follows: (1) age of 18 - 65 years; (2) not pregnancy/lactation during the study; (3) no previous injection at the site within 12 hours before the test; (4) full consciousness and ability to perceive and indicate pain and (5) no history of coagulation disorders (
Figure 1). The patients received the same injectable dose of enoxaparin (6,000 units). The patients who were unwilling to continue participation or were discharged earlier than 72 hours were excluded from the study.
Initially, random sampling was performed by the researcher to enroll the patients, followed by examining the complications after injection. The control group received the injection without an intervention using a standard injection technique, and the injection was performed in the right or left abdomen within five centimeters around the umbilicus to the sides with no aspiration within 10 seconds without massage after the injection.
The patients also received training on avoiding the manipulation of the injection site. Cold compress was applied at different intervals. In the first intervention group, the cold compress (water and ice bags) was applied five minutes prior to the injection. In the second group, the cold compress was applied 20 minutes following the injection. In the third intervention group, the cold compress was applied five minutes before and 20 minutes after the injection, and in the fourth group, the cold compress was applied five minutes before and five minutes after the injection.
Data were collected by a trained researcher using a researcher-made checklist consisting of two sections, which were demographic characteristics (age, gender, disease type) and pain intensity assessment by VAS. This standard instrument is used to measure pain intensity within a scale of 0 - 10, and the patient is asked to rate their perceived pain. VAS is a 100-millimeter ruler, and the patient indicated the level of pain within the mentioned scale (no pain = 0, moderate pain = 1 - 5, severe pain = 6 - 10); the measured accuracy of pain severity in this scale is based on the visual aspect. Notably, the validity, reliability, and sensitivity of VAS have been confirmed in several studies for acute, chronic, and cancerous pain. Accordingly, the validity of the scale is 76 - 86%, and the reliability is reported to be 60 - 77% (
10). In the present study, pain severity was measured immediately, 24, and 72 hours after the injection.
Data analysis was performed in SPSS version 16 (233, South Wacker Drive, 11th Floor, Chicago, USA) using descriptive statistics, independent t-test, and one-way analysis of variance (ANOVA). In all the statistical analyses, the significance level was set at 0.05.